Stock Events

Stock Events

Minerva Neurosciences 

$4.79
66
+$0.25+5.51% Wednesday 19:59
+$0.00+0%Wednesday 23:30After hours

Statistics

Day High
4.91
Day Low
4.7
52W High
12.46
52W Low
1.93
Volume
12,342
Avg. Volume
-
Mkt Cap
228.71M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.86
-1.95
-1.04
-0.13
Expected EPS
-0.166667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-293.42MNet Income

Analyst Ratings

10.33Average Price Target
The highest estimate is 14.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NERV. It's not an investment recommendation.
Microsoft
13
MSFT
Apple
12
AAPL
Tesla
12
TSLA
Amazon
12
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
Acadia Pharmaceuticals specializes in neurology, competing with Minerva in developing treatments for central nervous system disorders.
Alkermes
ALKS
Mkt Cap8.23B
Alkermes works on central nervous system (CNS) diseases, including schizophrenia and depression, areas Minerva is also targeting.
BridgeBio Pharma
BBIO
Mkt Cap15.61B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could overlap with Minerva's focus on neurological conditions.
Biogen
BIIB
Mkt Cap31B
Biogen is a major player in neurology, directly competing with Minerva in the broader market for neurological disease treatments.
AMGEN
AMGN
Mkt Cap224.63B
Amgen, with its broad focus on biopharmaceuticals, has ventures into neuroscience, making it a competitor in the neurology space.
Insmed
INSM
Mkt Cap27.02B
Insmed incorporates a wide range of therapeutic areas, including neurological diseases, indirectly competing with Minerva.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, which includes treatments for neurological disorders, competing with Minerva's focus.
Palatin Technologies
PTN
Mkt Cap16.65M
Palatin Technologies, though focused on different areas, has shown interest in expanding into central nervous system disorders, potentially competing with Minerva.

About

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Show more...
CEO
Remy Luthringer
Employees
7
Country
United States
ISIN
US6033802058
WKN
000A3DMH5

Listings

F
DE
4MNA.F
STU
DE
4MNA.STU
MU
DE
4MN.MU
MU
DE
4MNA.MU

0 Comments

Share your thoughts

FAQ

What is Minerva Neurosciences stock price today?▼
The current price of NERV is $4.79 USD — it has increased by +5.51% in the past 24 hours. Watch Minerva Neurosciences stock price performance more closely on the chart.
What is Minerva Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Minerva Neurosciences stocks are traded under the ticker NERV.
Is Minerva Neurosciences stock price growing?▼
NERV stock has risen by +22.19% compared to the previous week, the month change is a +9.61% rise, over the last year Minerva Neurosciences has showed a +108.44% increase.
What is Minerva Neurosciences market cap?▼
Today Minerva Neurosciences has the market capitalization of 228.71M
When is the next Minerva Neurosciences earnings date?▼
Minerva Neurosciences is going to release the next earnings report on November 11, 2026.
What were Minerva Neurosciences earnings last quarter?▼
NERV earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.19 USD resulting in a +27.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Minerva Neurosciences revenue for the last year?▼
Minerva Neurosciences revenue for the last year amounts to 0 USD.
What is Minerva Neurosciences net income for the last year?▼
NERV net income for the last year is -293.42M USD.
How many employees does Minerva Neurosciences have?▼
As of August 20, 2026, the company has 7 employees.
In which sector is Minerva Neurosciences located?▼
Minerva Neurosciences operates in the Health & Wellness sector.
When did Minerva Neurosciences complete a stock split?▼
The last stock split for Minerva Neurosciences was on June 21, 2022 with a ratio of 1:8.
Where is Minerva Neurosciences headquartered?▼
Minerva Neurosciences is headquartered in BURLINGTON, United States.